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The role of changes in blood-brain barrier permeabil- 
ity in the pathogenesis of hepatic encephalopathy re- 
mains uncertain. To test the hypothesis that brain mi- 
crovessel permeability is nonselectively increased in 
hepatic encephalopathy we measured the blood-brain 
barrier permeability-surface area product in rats with 
acute liver failure induced by intraperitoneal injection 
of galactosamine. The permeability-surface area prod- 
ucts to the diffusion-limited tracers, sucrose and 
methylaminoisobutyric acid, were determined as a 
measure of blood-brain barrier permeability. Animals 
were examined 24,36 and 42 hr after injection, at times 
when they were stuporous, but not comatose. No sig- 
nificant elevations of the permeability-surface area 
products for either compound were detected in clinically 
affected experimental animals when compared to con- 
trols. Our results indicate there is no generalized in- 
crease in brain vascular permeability during hepatic 
insufficiency in precomatose animals. 
The mechanism by which hepatic encephalopathy is 
produced remains unclear. Several investigators have 
reported increases in blood-brain barrier (BBB) perme- 
ability following experimental liver injury (1-3), and they 
propose that these changes play a role in the pathogen- 
esis of encephalopathy. Other investigators found no 
generalized BBB opening (4-6). This discrepancy may 
be explained, in part, by the low sensitivity of the method 
used to measure BBB permeability. Most of these studies 
employed the single-pass, intracarotid injection tech- 
nique. However, when used to measure brain uptake of 
poorly diffusible compounds, this method requires large 
corrections for tracer retained within the intravascular 
compartment (7). The integrity of the BBB can be meas- 
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ured more accurately with a technique developed by 
Ohno et al. (8). The BBB permeability-surface area 
product (PS) is determined following an intravenous 
injection of radiolabeled sucrose. The sucrose content in 
brain can be corrected for the intravascular portion by 
determining brain blood volume in a separate group of 
animals. We used this method to test the hypothesis that 
there is a generalized increase in BBB permeability dur- 
ing galactosamine-induced liver failure. 
MATERIALS AND METHODS 
Male Sprague-Dawley rats weigh- 
ing 250 to 350 gm were given an intraperitoneal injection of D+ 
galactosamine hydrochloride (3 gm per kg) as a 0.28 M solution 
(pH 7.4) in water (9, 10). Control animals were injected with 
0.28 M glucose in water. The animals were fed standard labo- 
ratory chow and 10 gm% glucose was added to their water. 
At 24, 36 and 42 hr after the galactosamine injection, the 
animals were anesthetized with sodium pentobarbital (50 mg 
per kg, i. p.) and tracheotomized. Polyethylene catheters were 
inserted into all four femoral vessels. The left femoral artery 
catheter was connected to a blood pressure transducer to mon- 
itor blood pressure as well as to collect blood-gas samples. The 
right femoral artery catheter was connected to a peristaltic 
pump to permit continuous arterial blood withdrawal. One 
venous catheter was used for intravenous injection of drugs 
while the other intravenous catheter was used for injection of 
radioactive tracers. 
The animals were paralyzed with gallamine, and ventilated 
using a volume ventilator set to maintain the arterial pC0, 
between 35 and 45 mm Hg. Temperature was monitored by a 
rectal probe and maintained at 36.5“ to 37.5’C with an  incan- 
descent lamp. 
Serum enzyme and bilirubin assays were performed in the 
clinical laboratory of the Columbus Children’s Hospital using 
a Kodak Ektachem-700‘” analyzer. 
For measurement of both BBB 
permeability (PS) and cerebral blood volume, the animals were 
allowed to reach a steady state 15 to 30 min following cannu- 
lation. Radioactive tracers were injected intravenously. During 
PS determinations, arterial blood was withdrawn from the right 
femoral artery at a known rate. When a predetermined amount 
of time had elapsed, a terminal arterial blood sample was 
collected from the left femoral artery, the animal was decapi- 
tated and the continuous arterial withdrawal was stopped. The 
forebrain was separated into right and left halves, then divided 
into cerebral hemispheres and basal ganglia. The brainstem 
was separated from the cerebellum. The brain regions were 
placed in preweighed scintillation vials containing Protosol and 
General Procedures. 
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reweighed. Blood from the continuous arterial withdrawal was 
expelled into a preweighed vial, weighed and 50 p1 aliquots were 
placed in scintillation vials containing a 2: 1 (volume/volume) 
mixture of ethano1:Protosol. The terminal arterial blood he- 
matocrit was measured, and 50-pl aliquots of the blood were 
also dissolved in ethano1:Protosol. Brain and blood samples 
were heated at 65°C until they were digested. The blood samples 
were bleached with 50 pl 30% hydrogen peroxide. Toluene- 
based scintillation cocktail was added to all samples, and the 
amount of radioisotope present was assayed by liquid scintil- 
lation using single or double channels as appropriate. 
Regional brain plasma 
volume and red blood cell volume were determined using a 
variation of a method previously described (11, 12). Homolo- 
gous rat red blood cells were incubated with 300 pCi 51Cr per 
1.2 ml packed cells for 30 min at 37°C. The labeled red cells 
were then washed three times with iced phosphate-buffered 
saline (PBS) containing 10 mM glucose and kept on ice. Just 
prior to use, a 200-pl aliquot of cells was washed with PBS and 
suspended with 100 .ul 1% bovine serum albumin (BSA) in PBS 
containing 10 pCi '"I-labeled BSA (1.39 pCi per mg BSA). The 
suspension was injected via the left femoral venous line. The 
labeled cells and plasma were allowed to circulate for 2 min, 
then a terminal arterial blood sample was rapidly withdrawn 
and the animal was decapitated. The samples were subse- 
quently handled as described in the general procedures. The 
radioactive content was determined in a two-channel liquid 
scintillation counter that was calibrated for simultaneous 
counting of the Auger and conversion electrons emitted by "Cr 
and "'I (13). Typical counting efficiencies were 20 and 20% for 
channel A, and 1 and 33% for channel B, for "Cr and '9, 
respectively. 
PS. A 10 pCi aliquot of [ ' 4 C ] ~ ~ ~ r ~ ~ e  (560 pCi per mmole) 
or ["C]methyl-aminoisobutyric acid [(MAIB), 40 to 60 mCi per 
mmole] in PBS was injected intravenously. Arterial blood was 
continuously withdrawn for 10 min, then a terminal blood 
sample was obtained and the animal was killed. Tissues and 
blood were handled as in general procedures. 
Cdculotions. Assuming that the PS for sucrose or MAIB 
is much less than the regional cerebral blood flow, and that the 
early brain concentration of either isotope is negligibly small 
(7), PS may be determined by the following relationship: 
Blood Volume Meaeurement. 
C b  P S  = ~ 
Cndt 
where CI, = the amount of' isotope in the brain region and C. = 
the amount of isotope in the arterial blood at  a given time, t. 
The integral of C.dt between the time of isotope injection and 
termination of' the experiment can be estimated by using a 
continuous arterial withdrawal at  a known rate using the fol- 
lowing equation: 
where C., = total amount of isotope in the arterial blood sample 
and F,, = the withdrawal rate of the pump (14). Knowing the 
tissue plasma volume (PV) ,  the following relationship can be 
made: 
- (Ct'PV) *Fn*(l - Hct.)/Cn I brain dpm brain weight PS = 
where C, = the terminal arterial concentration of isotope and 
Hct,, = the arterial hematocrit. PV is calculated from the 
lollowing equation using Hct. and values for regional blood 
volume (BV) and the ratio (R) of tissue to peripheral hemato- 
crits determined in a separate group of animals: 
PV = BV*(1 - Hct.*R). 
Thus, the plasma volume term takes into account any variabil- 
ity in peripheral hematocrits between groups of animals. 
M a t e r i d .  Animals were purchased from Harlan 
Sprague-Dawley, Inc. (Haslett, Mich.). Chemicals were ob- 
tained from Sigma Chemical Co. (St. Louis, Mo.) and were 
reagent grade. Protosol and a-[l-l4C]MAIB (48.4 mCi per 
mmole) were purchased from DuPont-NEN (Boston, Mass.). 
[ "C]Sucrose (10.0 mCi per mmole) and 'T-BSA (0.8 mCi per 
mg) were purchased from ICN (Irvine, Calif.). 
S t a t i s t i d  A d y e i s .  Results were assumed to be random 
samples that were mutually independent under the experimen- 
tal conditions. Because of small sample sizes, a normal distri- 
bution was not assumed, and nonparametric statistical tests 
were selected. For the data in Tables 1 to 4, results from three 
experimental animal groups were compared simultaneously 
with controls by the Kruskal-Wallis test using a = 0.01. For 
comparisons of the single MAIB uptake group to controls, the 
Mann-Whitney rank sum test was employed using the same a 
= 0.01 (15, 16). 
TABLE 1. Physiological parameters 
Control 24 br 36 hr 42 hr 
Regional blood volume determination 
animals 
Weight (gm) 
Blood pressure (mm Hg) 
Temperature ("0 
PH 
PCOS (mm Hg) 
PO) (mm Hg) 
Hematocrit 
PS determination animals 
Weight (gm) 
Blood pressure (mm Hg) 
Temperature ('C) 
PH 
pC0, (mm Hg) 
PO, (mm Hg) 
Hematocrit 
314 f 37 
1 1 8 f  13 
37.6 f 0.6 
7.39 f 0.04 
39 f 3 
9 4 f  15 















342 f 23 
81 f 20 
37.5 f 0.6 
7.37 f 0.04 
39 f 4 
125 f 9 
0.53 f 0.03 
212 f 31 
66 * 10 
3.68 f 0.6 
7.36 f 0.07 
40 f 5 
115 f 28 
0.41 f 0.04 
260 f 29 
97 f 23 
37.2 f 0.3 
7.28 f 0.09 
40 f 4 
86f 12 
0.53 f 0.02 
232 f 24 
80f 10 
37.4 f 0.5 
7.35 f 0.05 
38 f 3 
114 f 28 
0.47 f 0.03 
240 +- 19 
77 f 21 
37.4 f 0.9 
7.33 f 0.13 
39 f 2 
104 f 12 
0.51 f 0.04 
182 f 49 
a+ 12 
37.8 f 0.6 
7.30 f 0.1 
39 * 2 
111 f 14 
0.45 k 0.02 
Each value is the mean + S.D. of determinations from five animals 
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TABLE 2. Blood chemistry values in glactosamine-injected rats 
Control 24 hr 36 hr 42 hr 
AST (IU/liter) 120 f 37 9,499 f 9,383 15,234 f 6,545 7,753 f 3,973 
ALT (IU/liter) 53 f 6 4,395 f 5,264 13,454 f 6,559 5,687 f 3,128 
2.4 f 0.6 Total bilirubin (mg/dl) 0.3 f 0.1 1.1 f 0.8 3.3 f 1.6 
Direct bilirubin (mg/dl) 0.1 f 0.1 0.8 f 0.6 1.5 f 1.0 2.3 f 0.6 
Each value is the mean f S.D. of determinations from 5 to 7 animals. 
TABLE 3. Regional volume and hematocrit determinations 
Control 24 hr 36 hr 42 hr 
Tissue plasma 
volume" 
cortex 5.1 f 0.6 5.5 f 0 . 6  5.6 f 0.2 5.3 f 1.1 
Basal ganglia 6.6 f 1.4 6.8 f 0.8 7.0 f 0.8 7.0 f 0.6 
Cerebellum 7.7 f 1.0 8.4 f 0.9 8.9 f 1.0 8.5 f 0.5 
Brainstem 6.7 f 0.8 7.1 f 0.9 7.4 f 0.4 7.6 f 0.4 
Tissue red cell 
volume" 
cortex 1.8 f 0.2 2.4 f 0.2 2.1 f0 .2  2.1 f 0.7 
Basal ganglia 3.0 f 0.5 4.3 f 0.9 3.0 f 0.2 4.1 f 1.5 
Cerebellum 3.0 f 0.3 3.8f 0.4 3.9 f 1.0 3.6 f 0.8 
Brainstem 2.3 f 0.3 2.9 & 0.2 2.9f 0.6 3.1 f 0.6 
Tissue blood 
v o 1 u m e a 
cortex 7.0 f 0.8 7.8 f 0.8 7.7 f 0.2 7.67f 1.7 
Basal ganglia 9.6 f 1.3 11.1 f 1.6 10.1 f 0.9 11.1 f 1.6 
Cerebellum 10.7 f 1.1 12.2 f 1.2 12.9 f 1.9 12.1 f 0.9 
Brainstem 9.0 f 1.0 10.0 f 1.0 10.3 f 0.9 10.7 f 0.6 
Tissue hematocrit 
Cortex 0.26 f 0.01 0.30 f 0.02 0.27 f 0.02 0.28 f 0.05 
Basal ganglia 0.32 f 0.07 0.38 f 0.03 0.30 k 0.02 0.36 f 0.09 
Cerebellum 0.28 f 0.03 0.31 f 0.02 0.30 f 0.03 0.30 f 0.05 
Brainstem 0.26 f 0.02 0.29 f 0.02 0.28 f 0.04 0.29 f 0.05 
Each value is the mean f S.D. of determinations from five animals. 
a In pl/gm tissue weight. 
TABLE 4. Sucrose PS" determination 
Control 24 hr 36 hr 42 hr 
cortex 8.2 f 1.5 10.8f 3.2 7.4 f 1.2 8.5 f 1.9 
Basal ganglia 10.6 f 1.7 11.3 f 0.4 10.9 f 0.6 10.3 f 2.6 
Cerebellum 11.1 f 0.7 10.2 f 0.8 9.2 f 1.6 9.7 f 2.1 
Brainstem 9.6 f 2.4 10.6 f 2.2 8.8 f 1.9 10.4 f 2.3 
Each value is the mean f S.D. of determinations for five animals. 
In ml/gm/min x 10'. 
RESULTS 
At 24 hr after administration of galactosamine, the 
urine and plasma of the experimental rats were icteric, 
but the animals showed no behavioral difference from 
control animals. By 36 hr, the animals were listless, and 
they startled easily. A t  42 hr, the rats were awake, but 
poorly responsive to the environment. By this time, two 
animals had died after a period of irritability followed by 
stimulus-induced tonic seizures. When physiological pa- 
rameters were compared, animals a t  36 to 42 hr were 
more acidotic and hypotensive than the 24-hr experi- 
mental rats (Table 1). 
We measured serum aminotransferases, and total and 
direct bilirubin to characterize the extent of liver damage. 
In animals injected with glucose, values for AST, ALT, 
total bilirubin and direct bilirubin remained constant for 
at least 48 hr after injection (data not shown). In animals 
injected with galactosamine, serum aminotransferases 
steadily rose to a maximum at  36 hr after galactosamine 
injection and declined by 42 hr, although the aminotrans- 
ferase levels remained greater than control values (Table 
2). Serum direct bilirubin steadily increased above con- 
trol values after galactosamine injection at  all time points 
measured. All values at 24,36 and 42 hr were significantly 
different from controls (p < 0.01). The pronounced rise 
in serum aminotransferases and the progressing hyper- 
bilirubinemia point to the severity of galactosamine- 
induced hepatic injury. 
No significant increases from control values were 
noted in tissue plasma volumes, red cell volumes, blood 
volumes and tissue hematocrits in the cortex, basal gan- 
glia, cerebellum and brainstem of galactosamine-treated 
animals at 24,36 or 42 hr (Table 3). Brain blood volumes, 
expressed as microliters per gram of brain weight, did 
not vary with body weight in the animals examined 
(comparison not shown). The only multiple sample com- 
parisons that approached significance were an increase 
in tissue red cell volumes for the cortex (p = 0.037) and 
the brainstem (p = 0.049) when results a t  different time 
points were compared to controls. The differences were 
most notable between controls and 24-hr animals than 
at other times. 
PS was calculated for sucrose using the blood volumes 
shown in Table 2. At  all times following galactosamine 
injection, PS for affected animals did not differ signifi- 
cantly from controls (Table 4). This was true at  24 hr 
when animals were behaviorly unaffected as well as a t  
36 and 42 hr wheh their behavior was distinctly abnor- 
mal. 
Other investigators have reported significant increases 
in the regional PS product for aminoisobutyric acid in 
galactosamine-treated rabbits (2). In order to determine 
whether this observation was the result of a specific 
change in brain uptake of this type of amino acid analog, 
we determined the PS product for MAIB in rats 24 hr 
after galactosamine administration. We found no in- 
crease in PS for MAIB compared to controls. In fact, the 
MAIB-PS in all regions was lower than control (Table 
5). While MAIB enters the brain very poorly, it'is pos- 
sible that a portion of its brain uptake is mediated by an 
amino acid transport system. Reduced brain uptake of 
MAIB in galactosamine-treated rats might, therefore, be 
explained by competition for transport from the elevated 
plasma concentrations of other neutral amino acids dur- 
ing hepatic failure (17). 
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TABLE 5. MAIB PS Product" 
~~ ~ ~ 
Control 24 hr 9 d u e b  
Cortex 8.1 f 1.1 6.5 ? 0.9 0.012 
Basal ganglia 6.7 f 2.7 3.1 ? 1.3 0.07 
Cerebellum 10.9 f 1.7 - '  1.2f 1.3 0.018 
Brainstem 11.1 f 2.7 - 1.2 f 2.1 0.012 
Each value is the mean ? S.D. for six control and three experimental 




During the course of galactosamine-induced acute he- 
patic failure, we found no change in BBB permeability 
to sucrose despite the increasing duration of hepatic 
injury and progressive alterations in behavior. During 
the times studied, all animals showed evidence of severe 
liver damage. By 36 hr, they were less active and by 42 
hr they were either lethargic or hyperirritable, but not 
comatose. 
Our results are in agreement with other studies which 
found no change in BBB permeability following liver 
injury. In one study, rats with chronic portacaval shunts 
were given ammonium acetate to acutely induce enceph- 
alopathy (4). There was no difference in the brain uptake 
of sucrose compared with controls. A second study used 
a similar method without ammonia loading; no change 
in the BBB permeability to inulin was found (5) .  A third 
study found no change in brain uptake of "Na and "Cr- 
EDTA in rats examined 3 weeks after the creation of a 
portacaval shunt (6). These three studies used the intra- 
carotid bolus injection method to measure the brain 
uptake index, although this technique is relatively insen- 
sitive to changes in BBB permeability for poorly diffus- 
ible compounds. In a fourth study, Mans et al. (18) used 
the technique of quantitative autoradiography, which is 
more sensitive than the brain uptake index technique to 
determine BBB permeability to sucrose. They found no 
change in PS in rats examined 7 to 8 weeks after porta- 
caval shunting. Mans et al. did not examine BBB changes 
during acute hepatic encephalopathy. 
Our findings conflict with the observations of Zaki et 
al. (1) who employed the brain uptake index technique 
in galactosamine-induced hepatic failure and hepatic 
devascularization. They detected a 3- to 4-fold increase 
in the uptake of inulin and a %fold increase in the uptake 
of sucrose and L-glucose. The animals were examined in 
deep coma and were, therefore, more severely affected 
than the animals in the present study. It is possible, as 
those authors point out, that the detected changes in 
BBB permeability reflected the moribund state of the 
animals. 
Also, in contrast to our findings are the results of 
Horowitz et al. (2) who detected localized increases in 
BBB permeability in a rabbit model of galactosamine- 
induced hepatic failure. Using autoradiographic tech- 
niques to identify regional changes in isotope concentra- 
tions, the investigators examined the equilibrium trans- 
fer constant for ''C-labeled aminoisobutyric acid. At a 
time before the animals became encephalopathic, in- 
creases in the aminoisobutyric acid transfer constant 
occurred in the medial geniculate body, superior collicu- 
lus, central grey substance, area retrosplenius and lateral 
thalamic nucleus. Less pronounced changes were noted 
in the limbic regions, basal ganglia and temporal cortex. 
Other cortical regions and white matter tracts were un- 
affected. 
One possible explanation for the differences between 
our results and those of Horowitz et al. (2) is that the 
permeability change they observed is specific for ami- 
noisobutyric acid and not sucrose. Aminoisobutyric acid 
normally has a low BBB permeability because the carrier 
for which this amino acid analog has the highest affinity 
is found on the antiluminal but not the luminal mem- 
brane of the brain capillary endothelial cell (19). Re- 
distribution of this transport protein to the luminal 
membrane could result in a selective increase in BBB 
permeability to aminoisobutyric acid with no change in 
permeability to sucrose (20). The fact that BBB perme- 
ability to MAIB, a similar amino acid analog, did not 
increase in our model, makes this redistribution of car- 
riers unlikely. Alternatively, it is possible that the highly 
localized increases in BBB permeability detected by the 
autoradiographic method of Horowitz et al. could not be 
resolved by our method, which required analysis of larger 
pieces of brain containing many brain structures. 
We conclude that galactosamine-induced hepatic in- 
jury does not produce a generalized breakdown of the 
BBB in premoribund animals. However, it remains pos- 
sible that localized changes in BBB permeability may 
occur in specific brain regions. Future research should 
attempt to confirm that BBB permeability does increase 
in brain structures, like the medial geniculate body and 
the lateral thalamus, since an analysis of the causes and 
consequences of BBB breakdown in those regions could 
provide important insights into the pathogenesis of he- 
patic encephalopathy. 
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